Aprile Pilon's Company
Clarassance is developing novel protein drugs with game-changing potential to modify respiratory diseases, not just treat daily symptoms.
Clarassance is a clinical stage biotechnology company with lead product ready to enter Phase2 clinical trials for persistent sinusitis and in premature babies. There is an unmet need for new drugs to treat respiratory diseases that will be addressed by the company's products. The plan is to complete at least one Ph2 trial and then secure a large pharmaceutical partner. The desired exit is a sale of the company in 3-5 years.